Literature DB >> 25761856

Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.

Elisabetta Patorno1, Elizabeth M Garry, Amanda R Patrick, Sebastian Schneeweiss, Victoria G Gillet, Olesya Zorina, Dorothee B Bartels, John D Seeger.   

Abstract

A growing body of observational literature on the association between glucose-lowering treatments and all-cause mortality has been accumulating in recent years. However, many investigations present designs or analyses that inadequately address the methodological challenges involved. We conducted a systematic search with a non-systematic extension to identify observational studies published between 2000 and 2012 that evaluated the effects of glucose-lowering medications on all-cause mortality. We reviewed these studies and assessed the design and analysis methods used, with a focus on their ability to address specific methodological challenges. We described these methodological issues and their potential impact on observed associations, providing examples from the reviewed literature, and suggested possible approaches to manage these methodological challenges. We evaluated 67 publications of observational studies evaluating the association between glucose-lowering treatments and all-cause mortality. The identified methodological challenges included trade-offs associated with the outcome of all-cause mortality, incorrect temporal sequencing in administrative databases, inadequate treatment of time-varying hazards and treatment duration effects, unclear definition of the exposure risk window, improper handling of time-varying exposures, and incomplete accounting for confounding by indication. Most of these methodological challenges may be adequately addressed through the application of appropriate methods. Observational research plays an increasingly important role in assessing the clinical effects of diabetes therapy. The implementation of suitable research methods can reduce the potential for spurious findings, and thus the risk of misleading the medical community about benefits and harms of diabetes therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25761856     DOI: 10.1007/s40264-015-0280-1

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  112 in total

Review 1.  Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.

Authors:  Shibing Yang; Charles B Eaton; Juan Lu; Kate L Lapane
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-24       Impact factor: 2.890

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

3.  Confounding by indication.

Authors:  A M Walker
Journal:  Epidemiology       Date:  1996-07       Impact factor: 4.822

4.  Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.

Authors:  Soley Bayraktar; Leonel F Hernadez-Aya; Xiudong Lei; Funda Meric-Bernstam; Jennifer K Litton; Limin Hsu; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-07-28       Impact factor: 6.860

5.  Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

Authors:  X-X He; S M Tu; M-H Lee; S-C J Yeung
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

6.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

7.  Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.

Authors:  Alana Choy-Shan; Andrew Zinn; Binita Shah; Ann Danoff; Robert Donnino; Arthur Z Schwartzbard; Jeffrey D Lorin; Eugene Grossi; Steven P Sedlis
Journal:  Coron Artery Dis       Date:  2012-08       Impact factor: 1.439

8.  Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.

Authors:  Laurent Azoulay; Verena Schneider-Lindner; Sophie Dell'aniello; Alicia Schiffrin; Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-04       Impact factor: 2.890

9.  Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.

Authors:  Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin
Journal:  Ann Intern Med       Date:  2012-11-06       Impact factor: 25.391

10.  Overadjustment bias and unnecessary adjustment in epidemiologic studies.

Authors:  Enrique F Schisterman; Stephen R Cole; Robert W Platt
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

View more
  11 in total

1.  Flexible Modeling of the Association Between Cumulative Exposure to Low-Dose Ionizing Radiation From Cardiac Procedures and Risk of Cancer in Adults With Congenital Heart Disease.

Authors:  Coraline Danieli; Sarah Cohen; Aihua Liu; Louise Pilote; Liming Guo; Marie-Eve Beauchamp; Ariane J Marelli; Michal Abrahamowicz
Journal:  Am J Epidemiol       Date:  2019-08-01       Impact factor: 4.897

2.  Theory meets practice: a commentary on VanderWeele's 'principles of confounder selection'.

Authors:  Sebastian Schneeweiss
Journal:  Eur J Epidemiol       Date:  2019-03-06       Impact factor: 8.082

Review 3.  Common medications and prostate cancer mortality: a review.

Authors:  Konrad H Stopsack; Alexandra J Greenberg; Lorelei A Mucci
Journal:  World J Urol       Date:  2016-08-04       Impact factor: 4.226

4.  Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.

Authors:  Elisabetta Patorno; Chandrasekar Gopalakrishnan; Jessica M Franklin; Kimberly G Brodovicz; Elvira Masso-Gonzalez; Dorothee B Bartels; Jun Liu; Sebastian Schneeweiss
Journal:  Diabetes Obes Metab       Date:  2018-01-12       Impact factor: 6.577

Review 5.  Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.

Authors:  Elisabetta Patorno; Sebastian Schneeweiss; Shirley V Wang
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

6.  Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes.

Authors:  HoJin Shin; Sebastian Schneeweiss; Robert J Glynn; Elisabetta Patorno
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-01-17       Impact factor: 2.890

7.  Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes.

Authors:  Fu-Shun Yen; James Cheng-Chung Wei; Ying-Hsiu Shih; Wei-Lin Pan; Chih-Cheng Hsu; Chii-Min Hwu
Journal:  J Pers Med       Date:  2022-04-28

8.  The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.

Authors:  Elisabetta Patorno; Mehdi Najafzadeh; Ajinkya Pawar; Jessica M Franklin; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Adrian J Santiago Ortiz; Lily G Bessette; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Endocrinol Diabetes Metab       Date:  2019-11-26

Review 9.  Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Gian Paolo Fadini; Giulio Marchesini; Fabrizio De Ponti
Journal:  Diabetes Obes Metab       Date:  2018-08-14       Impact factor: 6.577

10.  The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study.

Authors:  Rianne M Douwes; António W Gomes-Neto; Michele F Eisenga; Elisabet Van Loon; Joëlle C Schutten; Rijk O B Gans; Maarten Naesens; Else van den Berg; Ben Sprangers; Stefan P Berger; Gerjan Navis; Hans Blokzijl; Björn Meijers; Stephan J L Bakker; Dirk Kuypers
Journal:  PLoS Med       Date:  2020-06-15       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.